Kabi Commands Respect As It Launches First Tocilizumab Biosimilar In Europe
Subcutaneous, Intravenous Forms ‘Will Transform Treatment Landscape’
Fresenius Kabi has kicked off November by launching its tocilizumab biosimilar Tyenne – the first biosimilar to Actemra to reach the EU.
